Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 90

1.

Bridging Crystal Engineering and Drug Discovery by Utilizing Intermolecular Interactions and Molecular Shapes in Crystals.

Spackman PR, Yu LJ, Morton CJ, Parker MW, Bond CS, Spackman MA, Jayatilaka D, Thomas SP.

Angew Chem Int Ed Engl. 2019 Aug 6. doi: 10.1002/anie.201906602. [Epub ahead of print]

PMID:
31385643
2.

The structure of the PA28-20S proteasome complex from Plasmodium falciparum and implications for proteostasis.

Xie SC, Metcalfe RD, Hanssen E, Yang T, Gillett DL, Leis AP, Morton CJ, Kuiper MJ, Parker MW, Spillman NJ, Wong W, Tsu C, Dick LR, Griffin MDW, Tilley L.

Nat Microbiol. 2019 Aug 5. doi: 10.1038/s41564-019-0524-4. [Epub ahead of print]

PMID:
31384003
3.

Altered Relationship between Working Memory and Brain Microstructure after Mild Traumatic Brain Injury.

Chung S, Wang X, Fieremans E, Rath JF, Amorapanth P, Foo FA, Morton CJ, Novikov DS, Flanagan SR, Lui YW.

AJNR Am J Neuroradiol. 2019 Sep;40(9):1438-1444. doi: 10.3174/ajnr.A6146. Epub 2019 Aug 1.

PMID:
31371359
4.

An Intermolecular π-Stacking Interaction Drives Conformational Changes Necessary to β-Barrel Formation in a Pore-Forming Toxin.

Burns JR, Morton CJ, Parker MW, Tweten RK.

MBio. 2019 Jul 2;10(4). pii: e01017-19. doi: 10.1128/mBio.01017-19.

5.

Cholesterol-Dependent Cytolysins: Membrane and Protein Structural Requirements for Pore Formation.

Morton CJ, Sani MA, Parker MW, Separovic F.

Chem Rev. 2019 Jul 10;119(13):7721-7736. doi: 10.1021/acs.chemrev.9b00090. Epub 2019 Jun 17.

PMID:
31244002
6.

A structure-based mechanism of cisplatin resistance mediated by glutathione transferase P1-1.

De Luca A, Parker LJ, Ang WH, Rodolfo C, Gabbarini V, Hancock NC, Palone F, Mazzetti AP, Menin L, Morton CJ, Parker MW, Lo Bello M, Dyson PJ.

Proc Natl Acad Sci U S A. 2019 Jul 9;116(28):13943-13951. doi: 10.1073/pnas.1903297116. Epub 2019 Jun 20.

7.

The Structural Basis for a Transition State That Regulates Pore Formation in a Bacterial Toxin.

Wade KR, Lawrence SL, Farrand AJ, Hotze EM, Kuiper MJ, Gorman MA, Christie MP, Panjikar S, Morton CJ, Parker MW, Tweten RK.

MBio. 2019 Apr 23;10(2). pii: e00538-19. doi: 10.1128/mBio.00538-19.

8.

The genetics, structure and function of the M1 aminopeptidase oxytocinase subfamily and their therapeutic potential in immune-mediated disease.

Hanson AL, Morton CJ, Parker MW, Bessette D, Kenna TJ.

Hum Immunol. 2019 May;80(5):281-289. doi: 10.1016/j.humimm.2018.11.002. Epub 2018 Nov 9. Review.

PMID:
30419264
9.

Protein structure and computational drug discovery.

Nero TL, Parker MW, Morton CJ.

Biochem Soc Trans. 2018 Oct 19;46(5):1367-1379. doi: 10.1042/BST20180202. Epub 2018 Sep 20. Review.

PMID:
30242117
10.

Cholesterol-dependent cytolysins: from water-soluble state to membrane pore.

Christie MP, Johnstone BA, Tweten RK, Parker MW, Morton CJ.

Biophys Rev. 2018 Oct;10(5):1337-1348. doi: 10.1007/s12551-018-0448-x. Epub 2018 Aug 16. Review.

11.

Characterization of Tfrc-mutant mice with microcytic phenotypes.

Conway AJ, Brown FC, Rank G, Kile BT, Morton CJ, Jane SM, Curtis DJ.

Blood Adv. 2018 Aug 14;2(15):1914-1922. doi: 10.1182/bloodadvances.2018018820.

12.

Bone marrow transplantation corrects haemolytic anaemia in a novel ENU mutagenesis mouse model of TPI deficiency.

Conway AJ, Brown FC, Hortle EJ, Burgio G, Foote SJ, Morton CJ, Jane SM, Curtis DJ.

Dis Model Mech. 2018 May 21;11(5). pii: dmm034678. doi: 10.1242/dmm.034678.

13.

Working Memory And Brain Tissue Microstructure: White Matter Tract Integrity Based On Multi-Shell Diffusion MRI.

Chung S, Fieremans E, Kucukboyaci NE, Wang X, Morton CJ, Novikov DS, Rath JF, Lui YW.

Sci Rep. 2018 Feb 16;8(1):3175. doi: 10.1038/s41598-018-21428-4.

14.

A dual role for the N-terminal domain of the IL-3 receptor in cell signalling.

Broughton SE, Hercus TR, Nero TL, Kan WL, Barry EF, Dottore M, Cheung Tung Shing KS, Morton CJ, Dhagat U, Hardy MP, Wilson NJ, Downton MT, Schieber C, Hughes TP, Lopez AF, Parker MW.

Nat Commun. 2018 Jan 26;9(1):386. doi: 10.1038/s41467-017-02633-7.

15.

White Matter Tract Integrity: An Indicator of Axonal Pathology after Mild Traumatic Brain Injury.

Chung S, Fieremans E, Wang X, Kucukboyaci NE, Morton CJ, Babb J, Amorapanth P, Foo FA, Novikov DS, Flanagan SR, Rath JF, Lui YW.

J Neurotrauma. 2018 Apr 15;35(8):1015-1020. doi: 10.1089/neu.2017.5320.

16.

Genetic Variants in ERAP1 and ERAP2 Associated With Immune-Mediated Diseases Influence Protein Expression and the Isoform Profile.

Hanson AL, Cuddihy T, Haynes K, Loo D, Morton CJ, Oppermann U, Leo P, Thomas GP, Lê Cao KA, Kenna TJ, Brown MA.

Arthritis Rheumatol. 2018 Feb;70(2):255-265. doi: 10.1002/art.40369. Epub 2017 Dec 29.

17.

Fragment library screening identifies hits that bind to the non-catalytic surface of Pseudomonas aeruginosa DsbA1.

Mohanty B, Rimmer K, McMahon RM, Headey SJ, Vazirani M, Shouldice SR, Coinçon M, Tay S, Morton CJ, Simpson JS, Martin JL, Scanlon MJ.

PLoS One. 2017 Mar 27;12(3):e0173436. doi: 10.1371/journal.pone.0173436. eCollection 2017.

18.

Transitional changes in the CRP structure lead to the exposure of proinflammatory binding sites.

Braig D, Nero TL, Koch HG, Kaiser B, Wang X, Thiele JR, Morton CJ, Zeller J, Kiefer J, Potempa LA, Mellett NA, Miles LA, Du XJ, Meikle PJ, Huber-Lang M, Stark GB, Parker MW, Peter K, Eisenhardt SU.

Nat Commun. 2017 Jan 23;8:14188. doi: 10.1038/ncomms14188.

19.

Glutathione transferase P1-1 as an arsenic drug-sequestering enzyme.

Parker LJ, Bocedi A, Ascher DB, Aitken JB, Harris HH, Lo Bello M, Ricci G, Morton CJ, Parker MW.

Protein Sci. 2017 Feb;26(2):317-326. doi: 10.1002/pro.3084. Epub 2016 Dec 14.

20.

Structural Basis for Receptor Recognition by the Human CD59-Responsive Cholesterol-Dependent Cytolysins.

Lawrence SL, Gorman MA, Feil SC, Mulhern TD, Kuiper MJ, Ratner AJ, Tweten RK, Morton CJ, Parker MW.

Structure. 2016 Sep 6;24(9):1488-98. doi: 10.1016/j.str.2016.06.017. Epub 2016 Aug 4.

21.

Sent packing: protein engineering generates a new crystal form of Pseudomonas aeruginosa DsbA1 with increased catalytic surface accessibility.

McMahon RM, Coinçon M, Tay S, Heras B, Morton CJ, Scanlon MJ, Martin JL.

Acta Crystallogr D Biol Crystallogr. 2015 Dec 1;71(Pt 12):2386-95. doi: 10.1107/S1399004715018519. Epub 2015 Nov 26.

22.

Crystal structure of Streptococcus pneumoniae pneumolysin provides key insights into early steps of pore formation.

Lawrence SL, Feil SC, Morton CJ, Farrand AJ, Mulhern TD, Gorman MA, Wade KR, Tweten RK, Parker MW.

Sci Rep. 2015 Sep 25;5:14352. doi: 10.1038/srep14352.

23.

The biological function of an insect antifreeze protein simulated by molecular dynamics.

Kuiper MJ, Morton CJ, Abraham SE, Gray-Weale A.

Elife. 2015 May 7;4. doi: 10.7554/eLife.05142.

24.

An intermolecular electrostatic interaction controls the prepore-to-pore transition in a cholesterol-dependent cytolysin.

Wade KR, Hotze EM, Kuiper MJ, Morton CJ, Parker MW, Tweten RK.

Proc Natl Acad Sci U S A. 2015 Feb 17;112(7):2204-9. doi: 10.1073/pnas.1423754112. Epub 2015 Feb 2.

25.

1,2,3,9b-Tetrahydro-5H-imidazo[2,1-a]isoindol-5-ones as a new class of respiratory syncytial virus (RSV) fusion inhibitors. Part 2: identification of BTA9881 as a preclinical candidate.

Bond S, Draffan AG, Fenner JE, Lambert J, Lim CY, Lin B, Luttick A, Mitchell JP, Morton CJ, Nearn RH, Sanford V, Anderson KH, Mayes PA, Tucker SP.

Bioorg Med Chem Lett. 2015 Feb 15;25(4):976-81. doi: 10.1016/j.bmcl.2014.11.024. Epub 2014 Nov 14.

PMID:
25595685
26.

The discovery of 1,2,3,9b-tetrahydro-5H-imidazo[2,1-a]isoindol-5-ones as a new class of respiratory syncytial virus (RSV) fusion inhibitors. Part 1.

Bond S, Draffan AG, Fenner JE, Lambert J, Lim CY, Lin B, Luttick A, Mitchell JP, Morton CJ, Nearn RH, Sanford V, Stanislawski PC, Tucker SP.

Bioorg Med Chem Lett. 2015 Feb 15;25(4):969-75. doi: 10.1016/j.bmcl.2014.11.018. Epub 2014 Nov 15.

PMID:
25595682
27.

Crystal structure of human insulin-regulated aminopeptidase with specificity for cyclic peptides.

Hermans SJ, Ascher DB, Hancock NC, Holien JK, Michell BJ, Chai SY, Morton CJ, Parker MW.

Protein Sci. 2015 Feb;24(2):190-9. doi: 10.1002/pro.2604. Epub 2014 Dec 26.

28.

Derivatives of imidazotriazine and pyrrolotriazine C-nucleosides as potential new anti-HCV agents.

Draffan AG, Frey B, Fraser BH, Pool B, Gannon C, Tyndall EM, Cianci J, Harding M, Lilly M, Hufton R, Halim R, Jahangiri S, Bond S, Jeynes TP, Nguyen VT, Wirth V, Luttick A, Tilmanis D, Pryor M, Porter K, Morton CJ, Lin B, Duan J, Bethell RC, Kukolj G, Simoneau B, Tucker SP.

Bioorg Med Chem Lett. 2014 Nov 1;24(21):4984-8. doi: 10.1016/j.bmcl.2014.09.030. Epub 2014 Sep 21.

PMID:
25288185
29.

The role of Rdl in resistance to phenylpyrazoles in Drosophila melanogaster.

Remnant EJ, Morton CJ, Daborn PJ, Lumb C, Yang YT, Ng HL, Parker MW, Batterham P.

Insect Biochem Mol Biol. 2014 Nov;54:11-21. doi: 10.1016/j.ibmb.2014.08.008. Epub 2014 Sep 1.

PMID:
25193377
30.

Discovery and in vivo evaluation of alcohol-containing benzothiazoles as potent dual-targeting bacterial DNA supercoiling inhibitors.

Palmer JT, Axford LC, Barker S, Bennett JM, Blair M, Collins I, Davies DT, Ford L, Gannon CT, Lancett P, Logan A, Lunniss CJ, Morton CJ, Offermann DA, Pitt GR, Rao BN, Singh AK, Shukla T, Srivastava A, Stokes NR, Thomaides-Brears HB, Yadav A, Haydon DJ.

Bioorg Med Chem Lett. 2014 Sep 1;24(17):4215-22. doi: 10.1016/j.bmcl.2014.07.037. Epub 2014 Jul 19.

PMID:
25086682
31.

Discovery and Synthesis of C-Nucleosides as Potential New Anti-HCV Agents.

Draffan AG, Frey B, Pool B, Gannon C, Tyndall EM, Lilly M, Francom P, Hufton R, Halim R, Jahangiri S, Bond S, Nguyen VT, Jeynes TP, Wirth V, Luttick A, Tilmanis D, Thomas JD, Pryor M, Porter K, Morton CJ, Lin B, Duan J, Kukolj G, Simoneau B, McKercher G, Lagacé L, Amad M, Bethell RC, Tucker SP.

ACS Med Chem Lett. 2014 Apr 10;5(6):679-84. doi: 10.1021/ml500077j. eCollection 2014 Jun 12.

32.

Mechanism of activation of protein kinase JAK2 by the growth hormone receptor.

Brooks AJ, Dai W, O'Mara ML, Abankwa D, Chhabra Y, Pelekanos RA, Gardon O, Tunny KA, Blucher KM, Morton CJ, Parker MW, Sierecki E, Gambin Y, Gomez GA, Alexandrov K, Wilson IA, Doxastakis M, Mark AE, Waters MJ.

Science. 2014 May 16;344(6185):1249783. doi: 10.1126/science.1249783.

33.

Potent hepatitis C inhibitors bind directly to NS5A and reduce its affinity for RNA.

Ascher DB, Wielens J, Nero TL, Doughty L, Morton CJ, Parker MW.

Sci Rep. 2014 Apr 23;4:4765. doi: 10.1038/srep04765.

34.

Oncogenic protein interfaces: small molecules, big challenges.

Nero TL, Morton CJ, Holien JK, Wielens J, Parker MW.

Nat Rev Cancer. 2014 Apr;14(4):248-62. doi: 10.1038/nrc3690. Epub 2014 Mar 13. Review.

PMID:
24622521
35.

An Orally Available 3-Ethoxybenzisoxazole Capsid Binder with Clinical Activity against Human Rhinovirus.

Feil SC, Hamilton S, Krippner GY, Lin B, Luttick A, McConnell DB, Nearn R, Parker MW, Ryan J, Stanislawski PC, Tucker SP, Watson KG, Morton CJ.

ACS Med Chem Lett. 2012 Feb 13;3(4):303-7. doi: 10.1021/ml2002955. eCollection 2012 Apr 12.

36.

Thiophene inhibitors of PDE4: crystal structures show a second binding mode at the catalytic domain of PDE4D2.

Nankervis JL, Feil SC, Hancock NC, Zheng Z, Ng HL, Morton CJ, Holien JK, Ho PW, Frazzetto MM, Jennings IG, Manallack DT, Martin TJ, Thompson PE, Parker MW.

Bioorg Med Chem Lett. 2011 Dec 1;21(23):7089-93. doi: 10.1016/j.bmcl.2011.09.109. Epub 2011 Oct 5.

PMID:
22030030
37.

Studies of glutathione transferase P1-1 bound to a platinum(IV)-based anticancer compound reveal the molecular basis of its activation.

Parker LJ, Italiano LC, Morton CJ, Hancock NC, Ascher DB, Aitken JB, Harris HH, Campomanes P, Rothlisberger U, De Luca A, Lo Bello M, Ang WH, Dyson PJ, Parker MW.

Chemistry. 2011 Jul 4;17(28):7806-16. doi: 10.1002/chem.201100586. Epub 2011 Jun 16.

PMID:
21681839
38.

Regulation of insulin-regulated membrane aminopeptidase activity by its C-terminal domain.

Ascher DB, Cromer BA, Morton CJ, Volitakis I, Cherny RA, Albiston AL, Chai SY, Parker MW.

Biochemistry. 2011 Apr 5;50(13):2611-22. doi: 10.1021/bi101893w. Epub 2011 Mar 9.

PMID:
21348480
39.

Phenylalanine-544 plays a key role in substrate and inhibitor binding by providing a hydrophobic packing point at the active site of insulin-regulated aminopeptidase.

Albiston AL, Pham V, Ye S, Ng L, Lew RA, Thompson PE, Holien JK, Morton CJ, Parker MW, Chai SY.

Mol Pharmacol. 2010 Oct;78(4):600-7. doi: 10.1124/mol.110.065458. Epub 2010 Jul 13.

PMID:
20628006
40.

Recognition and detoxification of the insecticide DDT by Drosophila melanogaster glutathione S-transferase D1.

Low WY, Feil SC, Ng HL, Gorman MA, Morton CJ, Pyke J, McConville MJ, Bieri M, Mok YF, Robin C, Gooley PR, Parker MW, Batterham P.

J Mol Biol. 2010 Jun 11;399(3):358-66. doi: 10.1016/j.jmb.2010.04.020. Epub 2010 Apr 24.

PMID:
20417639
41.

Influence of the H-site residue 108 on human glutathione transferase P1-1 ligand binding: structure-thermodynamic relationships and thermal stability.

Quesada-Soriano I, Parker LJ, Primavera A, Casas-Solvas JM, Vargas-Berenguel A, Barón C, Morton CJ, Mazzetti AP, Lo Bello M, Parker MW, García-Fuentes L.

Protein Sci. 2009 Dec;18(12):2454-70. doi: 10.1002/pro.253.

42.

Rational design of an organometallic glutathione transferase inhibitor.

Ang WH, Parker LJ, De Luca A, Juillerat-Jeanneret L, Morton CJ, Lo Bello M, Parker MW, Dyson PJ.

Angew Chem Int Ed Engl. 2009;48(21):3854-7. doi: 10.1002/anie.200900185.

PMID:
19396894
43.

Design of a conformationally defined and proteolytically stable circular mimetic of brain-derived neurotrophic factor.

Fletcher JM, Morton CJ, Zwar RA, Murray SS, O'Leary PD, Hughes RA.

J Biol Chem. 2008 Nov 28;283(48):33375-83. doi: 10.1074/jbc.M802789200. Epub 2008 Sep 22.

44.

Preventing serpin aggregation: the molecular mechanism of citrate action upon antitrypsin unfolding.

Pearce MC, Morton CJ, Feil SC, Hansen G, Adams JJ, Parker MW, Bottomley SP.

Protein Sci. 2008 Dec;17(12):2127-33. doi: 10.1110/ps.037234.108. Epub 2008 Sep 9.

45.

Identification and characterization of a new cognitive enhancer based on inhibition of insulin-regulated aminopeptidase.

Albiston AL, Morton CJ, Ng HL, Pham V, Yeatman HR, Ye S, Fernando RN, De Bundel D, Ascher DB, Mendelsohn FA, Parker MW, Chai SY.

FASEB J. 2008 Dec;22(12):4209-17. doi: 10.1096/fj.08-112227. Epub 2008 Aug 20.

PMID:
18716029
46.

Identification of modulating residues defining the catalytic cleft of insulin-regulated aminopeptidase.

Ye S, Chai SY, Lew RA, Ascher DB, Morton CJ, Parker MW, Albiston AL.

Biochem Cell Biol. 2008 Jun;86(3):251-61. doi: 10.1139/o08-037.

PMID:
18523486
47.

The anti-cancer drug chlorambucil as a substrate for the human polymorphic enzyme glutathione transferase P1-1: kinetic properties and crystallographic characterisation of allelic variants.

Parker LJ, Ciccone S, Italiano LC, Primavera A, Oakley AJ, Morton CJ, Hancock NC, Bello ML, Parker MW.

J Mol Biol. 2008 Jun 27;380(1):131-44. doi: 10.1016/j.jmb.2008.04.066. Epub 2008 May 4.

PMID:
18511072
48.

An updated unified pharmacophore model of the benzodiazepine binding site on gamma-aminobutyric acid(a) receptors: correlation with comparative models.

Clayton T, Chen JL, Ernst M, Richter L, Cromer BA, Morton CJ, Ng H, Kaczorowski CC, Helmstetter FJ, Furtmüller R, Ecker G, Parker MW, Sieghart W, Cook JM.

Curr Med Chem. 2007;14(26):2755-75. Review.

PMID:
18045122
49.

Molecular evolution of glutathione S-transferases in the genus Drosophila.

Low WY, Ng HL, Morton CJ, Parker MW, Batterham P, Robin C.

Genetics. 2007 Nov;177(3):1363-75.

50.

Copper binding to the Alzheimer's disease amyloid precursor protein.

Kong GK, Miles LA, Crespi GA, Morton CJ, Ng HL, Barnham KJ, McKinstry WJ, Cappai R, Parker MW.

Eur Biophys J. 2008 Mar;37(3):269-79. Epub 2007 Nov 21. Review.

Supplemental Content

Loading ...
Support Center